Driehaus Capital Management’s Climb Bio CLYM Stock Holding History

Driehaus Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	790,000 +189,054	+31%	+$1.95M	0.06%	274
2026 Q1	$4.12M	Hold	600,946	–	–	0.03%	292
2025 Q4	$2.4M	Buy	+600,946	New	+$1.44M	0.02%	329
2024 Q4	–	Sell	-612,387	Closed	-$3.12M	–	463
2024 Q3	$3.12M	Sell	612,387 -83,670	-12%	-$592K	0.03%	292
2024 Q2	$4.95M	Sell	696,057 -115,623	-14%	-$770K	0.05%	259
2024 Q1	$2.22M	Hold	811,680	–	–	0.02%	304
2023 Q4	$2.19M	Hold	811,680	–	–	0.03%	294
2023 Q3	$2.13M	Buy	811,680 +1,087	+0.1%	+$2.96K	0.03%	303
2023 Q2	$2.27M	Buy	810,593 +136,909	+20%	+$416K	0.03%	296
2023 Q1	$1.95M	Buy	673,684 +121,742	+22%	+$418K	0.03%	318
2022 Q4	$2.03M	Buy	551,942 +203,371	+58%	+$603K	0.03%	293
2022 Q3	$1.13M	Buy	+348,571	New	+$1.11M	0.02%	304

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Driehaus Capital Management's CLYM Position: Q2 2026 in Review

Driehaus Capital Management increased its Climb Bio (CLYM) stake by 31% in Q2 2026, buying an estimated $1.95M and bringing the position to 790,000 shares worth $10.3M. The position accounts for 0.06% of the portfolio, ranked #274.

Driehaus Capital Management first reported a position in CLYM in Q3 2022 and has held it in 12 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Driehaus Capital Management held 790,000 shares of Climb Bio worth $10.3M as of Q2 2026.
Driehaus Capital Management bought 189,054 Climb Bio shares in Q2 2026, an estimated $1.95M.
Climb Bio made up 0.06% of Driehaus Capital Management's portfolio in Q2 2026, its #274 holding.
Driehaus Capital Management first reported a position in Climb Bio in Q3 2022 and has held it in 12 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.